Regardless of the initial etiology (metabolic, alcoholic, or viral), progression to advanced SLD and HCC is governed by critical shared pathways, which are systemic metabolic dysregulation and inflammation
By Indication, Type 2 Diabetes mellitus leads the market, due to high prevalence, strong glycemic control, and clinical benefits Type 2 Diabetes Mellitus (T2DM) dominates the GLP-1 receptor agonist market, with a 61.7% share in 2025 , driven by its high global prevalence
Related Reading Intermittent Fasting Diet Lifemd Tirzepatide Goodlife Meds Tirzepatide Noom Tirzepatide Pricing and availability current as of June 2026
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach like other peptides and enhances its absorption
& Ando, W